Navigation Links
Sunesis Reports Financial Results for the First Quarter 2009
Date:5/6/2009

in in nonclinical studies, planned additional clinical testing and development efforts, the timing of clinical trial enrollment and the anticipated announcement of clinical results. Words such as "continued," "significant," "progress," "potential," " activity," established," "enhanced," "realize" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to Sunesis' need for additional funding, the risk that Sunesis' drug development activities could be halted significantly or delayed for various reasons, the risk that Sunesis' clinical trials for voreloxin may not demonstrate safety or efficacy or lead to regulatory approval, the risk that preliminary data and trends may not be predictive of future data or results, the risk that Sunesis' nonclinical studies and clinical trials may not satisfy the requirements of the FDA or other regulatory agencies, risks related to the conduct of Sunesis' clinical trials, including the pace of enrollment, risks related to the manufacturing of voreloxin and the risk that Sunesis' proprietary rights may not adequately protect voreloxin. These and other risk factors are discussed under "Risk Factors" and elsewhere in Sunesis' Annual Report on Form 10-K/A for the year ended December 31, 2008, its quarterly report on Form 10-Q for the quarter ended March 31, 2009 and other filings with the Securities and Exchange Commission. Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any chang
'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
2. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
3. Sunesis Pharmaceuticals SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
4. Sunesis Pharmaceuticals to Present at Healthcare Investor Conferences in March
5. Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
7. Sunesis Pharmaceuticals to Present at the Collins Stewart Fourth Annual Growth Conference
8. Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing
9. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
10. Haemacure Reports Third Quarter 2007 Results
11. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014 “Dr. Luciana Show – Aging and ... Dr. Luciana, is finding it challenging to stay on top ... care of hundreds of students, so the editing of the ... is completed, and she recently entered it into the festival ... of her husband, actor/screenwriter Gregory Graham , the aging ...
(Date:8/22/2014)... (ESMO), the leading pan-European organisation representing medical oncology ... individuals receiving the Society,s esteemed annual awards. The ... Joensuu and Peter Boyle on the occasion of ... , Carsten Bokemeyer will receive the ESMO Award ... cancer discovery into real benefit at patient level. ...
(Date:8/22/2014)... fainting. Each year approx. 265,000 Danes are acutely admitted ... research from Aarhus University and Aarhus University Hospital now ... every fourth patient are sent home again without ... to the acute hospitalisation., "Naturally, there is no need ... disprove that there is a serious illness. So some ...
(Date:8/22/2014)... Alzheimer,s disease can be slowed and some of ... is found in pomegranate. Also, the painful ... and Parkinson,s disease could be reduced, according to ... University of Huddersfield scientist Dr Olumayokun Olajide, who ... , Now, a new phase of research can ...
(Date:8/22/2014)... for the cancer Hodgkin lymphoma will be able to ... estimated their risk of premature menopause with different treatments. ... of the National Cancer Institute , are based on ... England and Wales treated for the cancer over a ... has suggested that women with Hodgkin lymphoma who receive ...
Breaking Medicine News(10 mins):Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 3Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 4Health News:ESMO honors outstanding oncology professionals 2Health News:ESMO honors outstanding oncology professionals 3Health News:Many patients are discharged without a diagnosis 2Health News:Research underway to create pomegranate drug to stem Alzheimer's and Parkinson's 2Health News:Scientists map risk of premature menopause after cancer treatment 2
... Nationally recognized asbestos ... written. , ... (PRWEB) April 15, 2010 -- Although most asbestos use was banned in the early 1980s, ... household and building products, says Joseph W. Belluck, a New York attorney who represents clients ...
... Traditional ... distributor. , ... April 15, 2010 -- Arsa Imports of El Paso, Texas, distributor of ... in Mexican culture, demonstrate that their most innovative items requested by today,s market, from ...
... study in the April 15 issue of the ... a sleep disturbance is associated with clinically meaningful reductions ... this effect varies by race and sleep disorder. ... African-Americans who snored frequently, had insomnia symptoms or reported ...
... is showing promise for the treatment of men with ... multicenter study has concluded that the targeted therapy MDV3100 ... cancer (CRPC), known for its poor prognosis and limited ... Sloan-Kettering Cancer Center, appears early online and in an ...
... ... comprehensive and successful anti-obesity program, First Lady Michelle Obama’s “Let’s Move” campaign must ... , ... (Vocus) April 14, 2010 -- To be a truly comprehensive and successful ...
... ... relief. , ... 2010 -- Spring is in full bloom and many Americans are beginning to experience the ... America, an estimated 50 million Americans have allergies, so for many the arrival of spring ...
Cached Medicine News:Health News:Asbestos Exposure Continues to Scar U.S. Workers and Their Families, New York Attorney Says 2Health News:Asbestos Exposure Continues to Scar U.S. Workers and Their Families, New York Attorney Says 3Health News:Arsa Offers High Quality Supplements, Cosmetics and Magic Scents from Mexico for Less Than $10 2Health News:The association between sleep disturbances and reduced quality of life varies by race 2Health News:The association between sleep disturbances and reduced quality of life varies by race 3Health News:New targeted therapy effective in treating advanced prostate cancer 2Health News:New targeted therapy effective in treating advanced prostate cancer 3Health News:Childhood Obesity Interventions Must Begin Early, UCSF Experts Say 2Health News:Childhood Obesity Interventions Must Begin Early, UCSF Experts Say 3Health News:Childhood Obesity Interventions Must Begin Early, UCSF Experts Say 4Health News:Spring is a Headache for Allergy Sufferers 2Health News:Spring is a Headache for Allergy Sufferers 3
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Eisai Limited is ... introduction of the first-of-its-kind comic book available in ... has been designed specifically to educate children and their parents ... Canada affecting more than 300,000 Canadians. Eisai is ... care (hhc) , in which the patient is central – ...
(Date:8/21/2014)... , Aug. 21, 2014 /PRNewswire-iReach/ -- ScriptPro ... Alliance (HITRUST) under its Common Security Framework (CSF). ... Security and Privacy Manager, "We appreciate this rigorous, ... of commitment that this certification signifies. Our business ... ABOUT THE CSF CERTIFICATION PROCESS: ScriptPro,s internal ...
(Date:8/21/2014)... Aug. 21, 2014  Henry Schein, Inc. (NASDAQ: ... and services to office-based dental, animal health and medical practitioners, ... conferences in September: , September 4, 2014 – ... , NY at 12:50 p.m. ET , September 8, 2014 ... New York , NY at 1:25 p.m. ET ...
Breaking Medicine Technology:Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2ScriptPro Achieves HITRUST Certification 2Henry Schein To Present At Two Investor Conferences In September 2
... ALBUQUERQUE, N.M., Sept. 2 Clinical Lab,Products ... BMOD),( http://www.biomoda.com ) and its proprietary early ... more promising advances in the cancer diagnostic,technology. ... makes particular,note of the assay,s simplicity that ...
... Invasive Surgery at St.,Luke,s-Roosevelt Hospital Center completes his ... benefiting from ,hidden scar, procedure, CUPERTINO, Calif., ... completion of a series of single port Lap-Band,procedures ... pain for,patients. Dr. Julio Teixeira at St. Luke,s-Roosevelt ...
Cached Medicine Technology:Clinical Lab Products Magazine Features Biomoda 2Novare Announces Successful Series of Single Port Lap Band Procedures With RealHand(R) High Dexterity Instruments 2Novare Announces Successful Series of Single Port Lap Band Procedures With RealHand(R) High Dexterity Instruments 3